ReviewMolecular biology reports2026
CRISPR/Cas‑driven biosensing: molecular mechanisms and advances in diagnostics.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of CRISPR-based technologies for DNA diagnostics represents a new epoch in providing technologies for DNA sequence-specific detection of any DNA target. By using the programmable, precise targeting capabilities associated with Cas effector proteins (e.g., Cas9 and Cas12), scientists have been able to repurpose these proteins with their inherent properties: high programmability, single base specificity, and collateral cleavage activity to develop novel, highly capable biosensors for DNA analysis. Unlike previous reviews, this work provides a systematic and mechanism-based classification of CRISPR/Cas biosensors, highlighting recent advances beyond conventional descriptive summaries. This review provides a comprehensive overview of the rapid evolution and application of CRISPR/Cas-based biosensors as a novel strategy for detecting a wide range of human health biomarkers, from nucleic acids to proteins and small molecules. First, we describe the principle of CRISPR/Cas system. Then, we critically analyze and compare the integration of CRISPR/Cas systems with distinct signal transduction strategies, with a dedicated focus on optical (photoelectrochemical, electrochemiluminescence, and fluorescence) and electrochemical readout platforms. Key technological breakthroughs, including ultra-sensitive detection in the attomolar-femtomolar range, advanced amplification strategies (e.g., RCA and EXPAR), and multiplex detection capabilities, are highlighted. Finally, we emphasize the clinical relevance, scalability challenges, and translational potential of these platforms, providing insights into their application in early disease diagnosis, real-time monitoring, and point-of-care testing. Overall, this review offers a critical perspective on current limitations and future directions, positioning CRISPR-based biosensors as promising tools for next-generation precision diagnostics and improved global health outcomes.
Indexed as
Identifiers
42201448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.